Hyaluronic-acid filler does not have to be dissolved before every eyelid operation. The decision depends on the product, location, volume, symptoms, tissue response, time since injection, and the planned surgery. Automatic dissolution can be as inappropriate as ignoring filler that is distorting the examination.
Why periorbital filler matters
Hyaluronic acid can persist longer than patients expect and can attract water. In the tear trough or cheek, it may contribute to fluctuating swelling, bluish discoloration, contour irregularity, or malar edema. It may also obscure hollows or change the apparent lid–cheek transition. However, stable filler outside the surgical field may not require treatment.
| Clinical situation | Possible plan | Why |
|---|---|---|
| Unknown product or location | Dermatologic ultrasound before treatment | Avoids blind injection or incorrect assumptions |
| Hyaluronic acid contributing to edema or distortion | Consider staged hyaluronidase | Allows reassessment after tissue response settles |
| Stable filler not affecting the plan | Observation may be reasonable | Routine dissolution is not always necessary |
| PMMA, silicone, biostimulator, or fat | Do not expect hyaluronidase to remove it | Hyaluronidase acts on hyaluronic acid |
The role of dermatologic ultrasound
Ultrasound can help identify whether material is present, its approximate plane and distribution, and signs of edema or inflammatory reaction. It does not replace clinical judgment, but it may improve planning when records are incomplete or the examination is unclear.
Patients should bring injection dates, product names, treated areas, volumes, and previous complication reports whenever possible. See the broader guide to facial injectables and surgical planning.
Hyaluronidase has limits and risks
Hyaluronidase may reduce hyaluronic-acid filler, but response can be incomplete or uneven and more than one session may be required. Temporary swelling, bruising, tenderness, contour change, and allergic reactions can occur. It should not be presented as a risk-free “reset,” and it does not dissolve PMMA, silicone, calcium hydroxyapatite, poly-L-lactic acid, or transferred fat.
After dissolution, the tissues need time to settle before a definitive surgical examination. The appropriate interval is individualized; fixed waiting periods are not reliable for every patient.
How filler affects Hybrid Blepharoplasty
Dr. June Favarin’s Hybrid Blepharoplasty distinguishes orbital bags, hollows, lid laxity, brow descent, skin quality, festoons, malar edema, and filler-related changes. Surgery may include conservative upper-eyelid treatment, transconjunctival lower-eyelid access, selective cantopexy, microfat, nanofat, or skin treatment—but only when indicated.
Recovery and warning signs
Prior filler can be one of several reasons for prolonged swelling, but surgery itself, lymphatic anatomy, festoons, allergies, medications, and combined procedures also matter. Read about expected swelling and warning signs after blepharoplasty.
International patients should complete assessment early enough to allow imaging, staged dissolution when needed, reassessment, and an appropriate stay for postoperative reviews. Concierge support can coordinate logistics, but diagnosis and timing remain medical decisions.
